Core 3: Bioinformatics and Biostatistics Core

点击翻译按钮获取中文摘要

SUMMARY The Emory Lung Cancer P01 application aims to decipher the underlying mechanisms of immunotherapy resistance of LKB1-mut lung cancer and to seek possible therapeutic solutions with three interconnected projects to address this urgent unmet medical need. The function of the Bioinformatics and Biostatistics Core (Core 3) is to provide robust and transparent analytic strategies, sophisticated and integrated data analysis and management platforms, and state-of-the-art methodologies to maximize the success of the overall program through guiding and fostering data-driven interactions and collaborations. To support this goal, our Core 3 team of investigators has complementary expertise and extensive experience in biostatistics, bioinformatics, and medical informatics and data management that is critical for rigorous experimental design and streamlined data analysis, interpretation, sharing and management for basic mechanism-driven examination and clinical studies. Specifically, we will (i) provide comprehensive biostatistical expertise and resources in support to Lung Cancer P01 projects, including novel clinical trial design; (ii) provide a new integrative computational platform to support the elucidation of the molecular basis for GDH1 (Project 1), IAP/STING (Project 2), and FAK (Project 3)- dependent tumorigenesis in LKB1-deficient lung cancer with project leaders; and (iii) develop and maintain a centralized data acquisition and management system that is customized explicitly for this P01. Core 3 serves as a focal point of the P01 to ensure data integrity, scientific rigor, and sharing; and to foster collaborations between projects based on integrated analysis of mechanistic and clinical results and close interactions with each project and Core 1 and Core 2 through a shared database. Serving as a critical component of the P01 Program, Core 3 will be critical to further safeguard and elevate the entire research quality in this P01 to support the development of the next generation of effective anticancer immunity-based therapeutic strategies for patients with LKB1 mutated lung cancer.